Aadi Bioscience Future Growth
Future criteria checks 2/6
Aadi Bioscience is forecast to grow earnings and revenue by 31.8% and 38.5% per annum respectively while EPS is expected to grow by 48.2% per annum.
Key information
31.8%
Earnings growth rate
48.2%
EPS growth rate
| Biotechs earnings growth | 27.7% |
| Revenue growth rate | 38.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 20 Dec 2024 |
Recent future growth updates
Recent updates
Lacklustre Performance Is Driving Aadi Bioscience, Inc.'s (NASDAQ:AADI) 27% Price Drop
Jul 03
Will Aadi Bioscience (NASDAQ:AADI) Spend Its Cash Wisely?
Jul 02Analyst Forecasts Just Became More Bearish On Aadi Bioscience, Inc. (NASDAQ:AADI)
May 10Improved Revenues Required Before Aadi Bioscience, Inc. (NASDAQ:AADI) Stock's 28% Jump Looks Justified
Mar 07Here's Why We're Watching Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Feb 12Why Investors Shouldn't Be Surprised By Aadi Bioscience, Inc.'s (NASDAQ:AADI) 48% Share Price Plunge
Dec 16Analysts Have Lowered Expectations For Aadi Bioscience, Inc. (NASDAQ:AADI) After Its Latest Results
Nov 10Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Oct 03Here's Why We're Not Too Worried About Aadi Bioscience's (NASDAQ:AADI) Cash Burn Situation
Jun 28Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Mar 04Aadi Bioscience highlights combination of KRAS inhibitors and nab-sirolimus for tumors
Oct 12A Look At The Fair Value Of Aadi Bioscience, Inc. (NASDAQ:AADI)
Sep 28Aadi Bioscience: Taking mTOR Inhibition To The Next Level
Sep 21Is Aadi Bioscience (NASDAQ:AADI) In A Good Position To Deliver On Growth Plans?
Jul 06Aadi Bioscience to enter Russell 2000 and Russell 3000 indexes
Jun 23What You Need To Know About The Aadi Bioscience, Inc. (NASDAQ:AADI) Analyst Downgrade Today
Nov 27Aadi Bioscience: FDA Approval Of Fyarro Only The Beginning
Nov 25Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 33 | -51 | -86 | N/A | 2 |
| 12/31/2025 | 52 | -21 | -66 | N/A | 3 |
| 12/31/2024 | 26 | -55 | -59 | N/A | 1 |
| 9/30/2024 | 25 | -62 | -56 | -54 | N/A |
| 6/30/2024 | 24 | -65 | -54 | -50 | N/A |
| 3/31/2024 | 24 | -69 | -61 | -58 | N/A |
| 12/31/2023 | 24 | -66 | -64 | -60 | N/A |
| 9/30/2023 | 23 | -63 | -65 | -61 | N/A |
| 6/30/2023 | 22 | -62 | -60 | -58 | N/A |
| 3/31/2023 | 19 | -62 | -53 | -52 | N/A |
| 12/31/2022 | 15 | -61 | -50 | -50 | N/A |
| 9/30/2022 | 11 | -63 | -51 | -51 | N/A |
| 6/30/2022 | 7 | -136 | -60 | -60 | N/A |
| 3/31/2022 | 3 | -119 | -52 | -52 | N/A |
| 12/31/2021 | 1 | -111 | -22 | -22 | N/A |
| 9/30/2021 | 14 | -87 | -13 | -13 | N/A |
| 6/30/2021 | 15 | -2 | 1 | 1 | N/A |
| 3/31/2021 | 15 | -6 | 2 | 2 | N/A |
| 12/31/2020 | 15 | -4 | -13 | -13 | N/A |
| 12/31/2019 | 1 | -13 | -8 | -8 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AADI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AADI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AADI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AADI's revenue (38.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: AADI's revenue (38.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AADI's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/29 12:05 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aadi Bioscience, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Burns | H.C. Wainwright & Co. |
| Roger Song | Jefferies LLC |
| Boris Peaker | TD Cowen |